Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V0UH
|
|||
| Former ID |
DNCL001698
|
|||
| Drug Name |
AMG 557
|
|||
| Indication | Sjogren syndrome [ICD-11: 4A43.20; ICD-10: M35, M35.0] | Phase 2 | [1] | |
| Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Phase 2 | [2] | ||
| Company |
Amgen Thousand
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B7-related protein 1 (B7RP1) | Target Info | Modulator | [3] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Intestinal immune network for IgA production | ||||
| Reactome | Costimulation by the CD28 family | |||
| WikiPathways | Costimulation by the CD28 family | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02334306) A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sj ren's Syndrome. U.S. National Institutes of Health. | |||
| REF 3 | Administration Of AMG 557, A Human Anti-B7RP-1 (ICOSL) Antibody, Leads To The Selective Inhibition Of Anti-KLH IgG Responses In Subjects With SLE: Results Of A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Sequential, Rising, Multiple-Dose Study. San Diego, CA October 25-30, 2013 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.